126 related articles for article (PubMed ID: 31486252)
21. Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial.
Bruna J; Videla S; Argyriou AA; Velasco R; Villoria J; Santos C; Nadal C; Cavaletti G; Alberti P; Briani C; Kalofonos HP; Cortinovis D; Sust M; Vaqué A; Klein T; Plata-Salamán C
Neurotherapeutics; 2018 Jan; 15(1):178-189. PubMed ID: 28924870
[TBL] [Abstract][Full Text] [Related]
22. Genetic association study of a polymorphic CAG repeats array of calcium-activated potassium channel (KCNN3) gene and schizophrenia among the Chinese population from Taiwan.
Tsai MT; Shaw CK; Hsiao KJ; Chen CH
Mol Psychiatry; 1999 May; 4(3):271-3. PubMed ID: 10395218
[TBL] [Abstract][Full Text] [Related]
23. Oxaliplatin-induced Peripheral Neuropathy in South Indian Cancer Patients: A Prospective Study in Digestive Tract Cancer Patients.
Palugulla S; Dkhar SA; Kayal S; Narayan SK
Indian J Med Paediatr Oncol; 2017; 38(4):502-507. PubMed ID: 29333020
[TBL] [Abstract][Full Text] [Related]
24. The Incidence of Oxaliplatin-Induced Peripheral Neurotoxicity at Khartoum Oncology Hospital: A Cross-Sectional Survey.
Ali NT; Mohamed AA; Yousef BA
Asia Pac J Oncol Nurs; 2020; 7(3):266-272. PubMed ID: 32642498
[TBL] [Abstract][Full Text] [Related]
25. The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study.
Chen XF; Wang R; Yin YM; Røe OD; Li J; Zhu LJ; Guo RH; Wu T; Shu YQ
Biomed Pharmacother; 2012 Jun; 66(4):279-84. PubMed ID: 22397758
[TBL] [Abstract][Full Text] [Related]
26. Updates on Oxaliplatin-Induced Peripheral Neurotoxicity (OXAIPN).
Argyriou AA
Toxics; 2015 May; 3(2):187-197. PubMed ID: 29056657
[TBL] [Abstract][Full Text] [Related]
27. Neurotoxicity Outcomes in a Population-based Cohort of Elderly Patients Treated With Adjuvant Oxaliplatin for Colorectal Cancer.
Raphael MJ; Fischer HD; Fung K; Austin PC; Anderson GM; Booth CM; Singh S
Clin Colorectal Cancer; 2017 Dec; 16(4):397-404.e1. PubMed ID: 28434884
[TBL] [Abstract][Full Text] [Related]
28. TRPA1 and TRPM8 Receptors May Promote Local Vasodilation that Aggravates Oxaliplatin-Induced Peripheral Neuropathy Amenable to 17β-Estradiol Treatment.
Pan Y; Chen F; Huang S; Cai Z; Lan H; Tong Y; Yu X; Zhao G
Curr Neurovasc Res; 2016; 13(4):309-317. PubMed ID: 27262300
[TBL] [Abstract][Full Text] [Related]
29. Acute changes in nerve excitability following oxaliplatin treatment in mice.
Makker PGS; White D; Lees JG; Parmar J; Goldstein D; Park SB; Howells J; Moalem-Taylor G
J Neurophysiol; 2020 Jul; 124(1):232-244. PubMed ID: 32519566
[TBL] [Abstract][Full Text] [Related]
30. Genetic polymorphisms of SCN9A are associated with oxaliplatin-induced neuropathy.
Sereno M; Gutiérrez-Gutiérrez G; Rubio JM; Apellániz-Ruiz M; Sánchez-Barroso L; Casado E; Falagan S; López-Gómez M; Merino M; Gómez-Raposo C; Rodriguez-Salas N; Tébar FZ; Rodríguez-Antona C
BMC Cancer; 2017 Jan; 17(1):63. PubMed ID: 28103821
[TBL] [Abstract][Full Text] [Related]
31. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer.
Argyriou AA; Cavaletti G; Briani C; Velasco R; Bruna J; Campagnolo M; Alberti P; Bergamo F; Cortinovis D; Cazzaniga M; Santos C; Papadimitriou K; Kalofonos HP
Cancer; 2013 Jan; 119(2):438-44. PubMed ID: 22786764
[TBL] [Abstract][Full Text] [Related]
32. Is quantitative sensory testing helpful in the management of oxaliplatin neuropathy? a two-year clinical study.
Delmotte JB; Beaussier H; Auzeil N; Massicot F; Laprévote O; Raymond E; Coudoré F
Cancer Treat Res Commun; 2018; 17():31-36. PubMed ID: 30343217
[TBL] [Abstract][Full Text] [Related]
33. Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer.
Lucchetta M; Lonardi S; Bergamo F; Alberti P; Velasco R; Argyriou AA; Briani C; Bruna J; Cazzaniga M; Cortinovis D; Cavaletti G; Kalofonos HP
Cancer Chemother Pharmacol; 2012 Dec; 70(6):899-902. PubMed ID: 23108696
[TBL] [Abstract][Full Text] [Related]
34. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
[TBL] [Abstract][Full Text] [Related]
35. Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity.
Velasco R; Alemany M; Villagrán M; Argyriou AA
J Pers Med; 2021 Jul; 11(7):. PubMed ID: 34357136
[TBL] [Abstract][Full Text] [Related]
36. Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?
Nichetti F; Falvella FS; Miceli R; Cheli S; Gaetano R; Fucà G; Infante G; Martinetti A; Antoniotti C; Falcone A; Di Bartolomeo M; Cremolini C; de Braud F; Pietrantonio F
Pharmacogenomics J; 2019 Oct; 19(5):465-472. PubMed ID: 30713338
[TBL] [Abstract][Full Text] [Related]
37. Liability of the voltage-gated sodium channel gene SCN2A R19K polymorphism to oxaliplatin-induced peripheral neuropathy.
Argyriou AA; Antonacopoulou AG; Scopa CD; Kottorou A; Kominea A; Peroukides S; Kalofonos HP
Oncology; 2009; 77(3-4):254-6. PubMed ID: 19738391
[TBL] [Abstract][Full Text] [Related]
38. Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy?
Antonacopoulou AG; Argyriou AA; Scopa CD; Kottorou A; Kominea A; Peroukides S; Kalofonos HP
Eur J Neurol; 2010 Jul; 17(7):963-8. PubMed ID: 20192979
[TBL] [Abstract][Full Text] [Related]
39. Oxaliplatin-induced neurotoxicity and the development of neuropathy.
Krishnan AV; Goldstein D; Friedlander M; Kiernan MC
Muscle Nerve; 2005 Jul; 32(1):51-60. PubMed ID: 15880395
[TBL] [Abstract][Full Text] [Related]
40. CAG repeat polymorphism within the KCNN3 gene is a significant contributor to susceptibility to anorexia nervosa: a case-control study of female patients and several ethnic groups in the Israeli Jewish population.
Koronyo-Hamaoui M; Gak E; Stein D; Frisch A; Danziger Y; Leor S; Michaelovsky E; Laufer N; Carel C; Fennig S; Mimouni M; Apter A; Goldman B; Barkai G; Weizman A
Am J Med Genet B Neuropsychiatr Genet; 2004 Nov; 131B(1):76-80. PubMed ID: 15389773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
